Evidence map›Paper›PMID 27391604›Full record

Trial reportPloS one2016

Detection and Quantification of Mycobacterium tuberculosis in the Sputum of Culture-Negative HIV-infected Pulmonary Tuberculosis Suspects: A Proof-of-Concept Study.

Guillermo Madico, Moses Mpeirwe, Laura White, Solange Vinhas, Beverley Orr, Patrick Orikiriza, Nancy S Miller, Mary Gaeddert, Juliet Mwanga-Amumpaire, Moises Palaci and 5 more

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. The Role of GeneXpertTropical medicine and infectious disease · 2023
    Article
  4. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019
    Article
  5. Article
  6. Fluoromycobacteriophages Can Detect ViableFrontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guillermo MadicoSection of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts, United States of America.
Moses MpeirweEpicentre, Médecins sans Frontières, Mbarara, Uganda.
Laura WhiteDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Solange VinhasNúcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.
Beverley OrrClinical Microbiology Laboratory, Boston Medical Center, Boston, Massachusetts, United States of America.
Patrick OrikirizaEpicentre, Médecins sans Frontières, Mbarara, Uganda.
Nancy S MillerClinical Microbiology Laboratory, Boston Medical Center, Boston, Massachusetts, United States of America.
Mary GaeddertSection of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts, United States of America.
Juliet Mwanga-AmumpaireEpicentre, Médecins sans Frontières, Mbarara, Uganda.
Moises PalaciNúcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.
Barry KreiswirthPublic Health Research Institute (PHRI) - Rutgers University, Newark, New Jersey, United States of America.
Joe StraightThisis Diagnostics Inc., Boston, Massachusetts, United States of America.
Reynaldo DietzeNúcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, Brazil.
Yap BoumEpicentre, Médecins sans Frontières, Mbarara, Uganda.
Edward C Jones-LópezSection of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleRapid diagnosis of pulmonary tuberculosis (TB) is critical for timely initiation of treatment and interruption of transmission. Yet, despite recent advances, many patients remain undiagnosed. Culture, usually considered the most sensitive diagnostic method, is sub-optimal for paucibacillary disease.

methodsWe evaluated the Totally Optimized PCR (TOP) TB assay, a new molecular test that we hypothesize is more sensitive than culture. After pre-clinical studies, we estimated TOP's per-patient sensitivity and specificity in a convenience sample of 261 HIV-infected pulmonary TB suspects enrolled into a TB diagnostic study in Mbarara, Uganda against MGIT culture, Xpert MTB/RIF and a composite reference standard. We validated results with a confirmatory PCR used for sequencing M. tuberculosis. MEASUREMENTS AND

resultsUsing culture as reference, TOP had 100% sensitivity but 35% specificity. Against a composite reference standard, the sensitivity of culture (27%) and Xpert MTB/RIF (27%) was lower than TOP (99%), with similar specificity (100%, 98% and 87%, respectively). In unadjusted analyses, culture-negative/TOP-positive patients were more likely to be older (P<0·001), female (P<0·001), have salivary sputum (P = 0·05), sputum smear-negative (P<0.001) and less advanced disease on chest radiograph (P = 0.05). M. tuberculosis genotypes identified in sputum by DNA sequencing exhibit differential growth in culture.

conclusionsThese findings suggest that the TOP TB assay is accurately detecting M. tuberculosis DNA in the sputum of culture-negative tuberculosis suspects. Our results require prospective validation with clinical outcomes. If the operating characteristics of the TOP assay are confirmed in future studies, it will be justified as a "TB rule out" test.

Indexed as

High-Throughput Nucleotide SequencingPolymerase Chain ReactionSputumAdultFemaleHIV InfectionsHumansMaleMiddle AgedMycobacterium tuberculosisTuberculosis, PulmonaryUganda

Identifiers

PMID27391604
PMCPMC4938528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.